Clinical breast cancer最新文献

{"title":"Clinical outcomes by histologic pattern of early-stage metaplastic breast cancer: A single-institution retrospective study.","authors":"Ashley Matusz-Fisher, Annabel Chen, Erin E Donahue, Courtney R Schepel, Michelle L Wallander, Chad A Livasy, Richard L White, Antoinette R Tan, Lejla Hadzikadic-Gusic","doi":"10.1016/j.clbc.2025.04.022","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.022","url":null,"abstract":"<p><strong>Purpose: </strong>Metaplastic breast cancer (MpBC) is a rare, aggressive type of breast cancer composed of several histologic patterns. This study evaluated outcomes among the MpBC histologic patterns, which include spindle cell/sarcomatous, squamous, heterologous mesenchymal, and mixed.</p><p><strong>Patients and methods: </strong>A retrospective chart review identified patients with early-stage MpBC diagnosed between January 1, 2010, and September 1, 2021. A matched control patient cohort with nonmetaplastic triple-negative breast cancer (TNBC) was selected. Associations between MpBC histologic patterns and disease characteristics were evaluated using chi-squared and Wilcoxon tests. Kaplan-Meier estimates and log rank tests assessed differences in recurrence-free survival (RFS) and overall survival (OS).</p><p><strong>Results: </strong>In the MpBC cohort (n = 106), histologic patterns included spindle cell/sarcomatous (34%), squamous (16%), heterologous mesenchymal (31%), mixed (18%), and other (1%). In patients with MpBC who received neoadjuvant chemotherapy (n = 32), residual cancer burden (RCB) was not found to be significantly different between the spindle cell/sarcomatous pattern versus other patterns (P = .81). In the entire MpBC cohort, patients with the spindle cell/sarcomatous pattern had inferior RFS (P = .02) and OS (P = .004) compared to patients with other patterns. There was no significant difference in RFS (P = .90) or OS (P = .90) between the MpBC and TNBC cohort.</p><p><strong>Conclusion: </strong>RCB did not differ among the MpBC histologic patterns, but outcomes were inferior in patients with the spindle cell/sarcomatous pattern. Outcomes were also inferior in patients with MpBC receiving neoadjuvant versus adjuvant chemotherapy. Our study did not find a difference in outcomes between patients with MpBC versus nonmetaplastic TNBC. More investigation with larger sample sizes and biomarkers is warranted.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.","authors":"Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Dame Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Thomas Boulet, Valentine Revelant, Nathalie Theron, Peter Trask, Laurentia Wahyudi, Zuzana Kirchmayer Machackova, Ljiljana Stamatovic","doi":"10.1016/j.clbc.2025.04.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.016","url":null,"abstract":"<p><strong>Background: </strong>We assessed long-term safety, efficacy, and health-related quality of life during the continuation phase after 3 years' follow-up in PHranceSCa (NCT03674112).</p><p><strong>Patients and methods: </strong>This was a randomized, open-label, international, multicenter, crossover, Phase II study in adjuvant HER2-positive early breast cancer. One hundred fifty nine patients received 3 cycles of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC), then 3 of intravenous pertuzumab and trastuzumab (P + H IV), or vice versa. Postcrossover, patients continued preferred treatment (≤ 18 cycles total).</p><p><strong>Results: </strong>Most adverse events, including all cardiac events (n = 2) and anaphylaxis/hypersensitivity (n = 3) were grade 1/2. None were grade 4/5. Grade 1/2 local injection-site reactions occurred in 13 patients (9.4%) receiving PH FDC SC. Other events occurred at comparable rates between arms. The overall event-free rate for invasive disease-free survival was 94.17% (95% confidence interval, 90.47-97.87) at 3 years; overall survival was 98.71% (96.92-100). Meaningful changes from baseline in health-related quality of life included improvements in role and social functioning, and reductions in financial difficulty.</p><p><strong>Conclusion: </strong>PH FDC SC was well tolerated, with safety consistent with that of P + H IV (except local injection-site reactions) and no grade ≥ 3 anaphylaxis/hypersensitivity or new safety signals in the continuation period. Immature efficacy data showed high event-free rates, consistent with the known clinical benefit of pertuzumab and trastuzumab (although follow-up was relatively short at 3 years). PHranceSCa adds to the totality of evidence reinforcing the long-term clinical benefit and safety of pertuzumab and trastuzumab.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mitochondrial Signature for Predicting Outcome of Early-Stage Breast Cancer by Machine Learning.","authors":"Yanni Li, Kristina Sundquist, Xiao Wang, Jan Sundquist, Ashfaque A Memon","doi":"10.1016/j.clbc.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.020","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer, a leading female cancer worldwide, can be influenced by mitochondrial dysfunction. Dysregulation of mitochondria by the nuclear genome may cause breast cancer initiation and progression. However, the comprehensive investigation of mitochondrial-related genes as prognostic marker for the overall survival of early-stage breast cancer patients is still limited.</p><p><strong>Methods: </strong>To address this, we employed machine learning methods to identify a concise set of mitochondrial-related genes with high accuracy and reliability in predicting survival outcomes. Bulk transcriptome collected from Sweden Cancerome Analysis Network - Breast (SCANB) was divided into training and testing datasets and the Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) was included as the external validation cohort. The 1136 known mitochondrial-related genes were analysed using univariate Cox regression, bootstrap and Lasso Cox regression in the SCANB training cohort for model construction.</p><p><strong>Results: </strong>We identified a 14-gene mitochondrial signature that independently predicts the survival outcome of breast cancer (adjusted hazard ratio [HR]: 2.08, 95% confidence interval [CI]: 1.20-3.62) in the SCANB dataset. A highly predictive nomogram was further constructed by integrating the mitochondrial signature with clinical variables, enabling robust prediction of overall survival at 1-, 3- and 5-year. This model demonstrated strong predictive capability in both the training cohort (the area under the receiver operating characteristic [ROC] curve [AUC]: 0.84, 0.79, 0.78) and validation cohort (AUC: 0.92, 0.83, 0.78).</p><p><strong>Conclusion: </strong>In this study, we suggested a novel mitochondrial signature model by comprehensively analysing mitochondrial-related genes, which have the potential to accurately predict the clinical prognosis at the early stages of breast cancer.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Based Automatic Mitosis Scoring in Breast Cancer Improves Inter-Observer Concordance and Efficiency.","authors":"Chien-Hui Wu, Min-Hsiang Chang, Hui-Juan Chen, Hsin-Hsiu Tsai, Chun-Jui Chien, Jian-Chiao Wang","doi":"10.1016/j.clbc.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.021","url":null,"abstract":"<p><strong>Background: </strong>Evaluation of mitotic activity is crucial for breast cancer treatment; however, manual scoring is imprecise, with considerable inter-observer variation, but comprehensive image analysis may address this problem. We designed an artificial intelligence-based workflow for automatic mitosis scoring of breast cancer images.</p><p><strong>Materials and methods: </strong>Ninety-three cases, including 117 whole-slide images, were enrolled and 97 images were used to train the mitosis detection model. The annotation of the first dataset was guided by phosphohistone-H3 immunohistochemical restraining to build an auxiliary label model. The second dataset was expanded to include interactive learning. The automatic scoring framework included image partitioning, epithelial area segmentation, mitosis detection, hotspot analysis, and score classification. Clinical utility was evaluated by 3 pathologists using 20 slide images.</p><p><strong>Results: </strong>The mitosis model achieved an F1-score of 0.75, which is comparable to that of other state-of-the-art algorithms. The automatic scoring workflow located hotspots by thoroughly analyzing the entire slide, which improved inter-pathologist concordance, but slightly underestimated the mitosis score. In addition, the reading time decreased significantly from an average of 452 s to 52 s for each case (P < .01).</p><p><strong>Conclusion: </strong>This study demonstrated that an integrated automatic mitosis scoring system could boost pathology end users to efficiently achieve higher concordance, providing a solid foundation for precision medicine. Novel methodologies are essential in assessing mitotic activity in the era of digital pathology.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding.","authors":"Carlos Eduardo Paiva, Vitor Souza Guimarães, Alinne Tatiane Faria Silva, Yara Cristina de Paiva Maia, Bianca Sakamoto Ribeiro Paiva, Tomás Reinert, Nathalie LeVasseur","doi":"10.1016/j.clbc.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.019","url":null,"abstract":"<p><p>In the landscape of breast cancer management, precise assessment of endocrine sensitivity significantly influences therapeutic strategies. The utilization of Ki67, an immunohistochemical marker of tumor proliferation, in tumor rebiopsy holds paramount importance in unraveling breast cancer's response to endocrine therapy. This narrative review aims to elucidate the pivotal role of Ki67 in endocrine sensitivity assessment. We explore the nuanced process of Ki67 evaluation, its timing, and its implications for clinical outcomes in breast cancer patients. From a clinical perspective to pathological response and risk of recurrence, we navigate the spectrum of Ki67's impact. By delving into these facets, we underscore Ki67's potential to guide personalized treatment strategies, shedding light on the intricate interplay between endocrine therapy and clinical outcomes in breast cancer patients.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computer-Aided Diagnosis of ER-positive, HER2-Negative Breast Cancer on Dynamic Contrast-Enhanced MRI: Associations With Oncotype DX Recurrence Scores.","authors":"Jin Joo Kim, Jin You Kim, Lee Hwangbo, Hojun Lee","doi":"10.1016/j.clbc.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.014","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether kinetic features derived from computer-aided diagnosis (CAD) and their heterogeneity at dynamic contrast-enhanced MRI are associated with the risk of breast cancer recurrence in patients with ER-positive, HER2-negative invasive breast cancer who have undergone the Oncotype DX assay.</p><p><strong>Methods: </strong>We retrospectively evaluated 227 women (mean age, 53 years) with newly diagnosed ER-positive, HER2-negative breast cancer who had undergone preoperative MRI and the Oncotype DX assay between 2018 and 2022. The enhancement kinetic parameters and their kinetic heterogeneity for each breast cancer were assessed using a CAD system and correlated with the Oncotype DX RS.</p><p><strong>Results: </strong>Of the 227 cancers, 61 (26.9%) had low (< 11), 141 (62.1%) had intermediate (11-25), and 25 (11.0%) had high (≥ 26) RS. The high-risk group (RS ≥ 26) had significantly higher mean Angio volume and kinetic heterogeneity on CAD compared to the nonhigh-risk group (RS < 26) (2.52 cm³ vs. 1.42 cm³, P = .023; .78 vs. .62, P = .025). Multivariate regression showed that higher kinetic heterogeneity (odds ratio [OR] 12.57, P = .024), high histologic grade (grade 3; OR 21.30, P< .001), progesterone receptor negativity (OR 21.30, P = .005) and higher Ki-67 (≥ 25%; OR 21.30, P= .006) were associated with a high-risk of recurrence.</p><p><strong>Conclusion: </strong>Higher kinetic heterogeneity on CAD was associated with an increased risk of recurrence in patients with ER-positive, HER2-negative breast cancer.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer.","authors":"Yael Berner-Wygoda, Meredith Li, Chloe Perlon, Diego Malon, Neha Pathak, Massimo Di Iorio, Jacqueline Savill, Amal Aljuhani, Michelle B Nadler, Eitan Amir","doi":"10.1016/j.clbc.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.017","url":null,"abstract":"<p><strong>Background: </strong>Traditionally, in neoadjuvant anthracycline-based chemotherapy for early-stage HER2+ breast cancer, paclitaxel is administered weekly for 12 doses combined with trastuzumab every 3 weeks (ACTH-W). In Ontario Canada, an alternative protocol consists of administering paclitaxel every 2 weeks concurrently with trastuzumab every 2 weeks for 4 doses (ACTH-O).</p><p><strong>Methods: </strong>We conducted a retrospective, single-institution chart review of sequential patients treated between 2014 and 2023 to evaluate the efficacy, safety, and resource utilization of ACTH-O compared with FEC-DH, TCH, and ACTH-W.</p><p><strong>Results: </strong>A total of 300 patients were included in this analysis. There was no statistically significant difference in pCR rates between ACTH-O (37.1%), FEC-DH (33.6%), and TCH (48.0%). Although the odds of achieving pCR was higher with ACTH-W than ACTH-O, disease-free survival at 3 years did not differ between any of the regimens (93.4% for ACTH-O, 90% for ACTH-W, 87.9% for 93.3 FEC-DH). Discontinuation was less frequent with ACTH-O, with similar rare cardiotoxicity events across all regimens. The minimum number of planned healthcare in-person visits for ACTH-O was half that of ACTH-W. The estimated cost of treatment administration was reduced by approximately one third, an important consideration in a resource-constrained healthcare system.</p><p><strong>Conclusion: </strong>ACTH-O regimen is a viable alternative to standard anthracycline-based regimens in HER2+ early breast cancer. It offers similar long-term outcomes while reducing time toxicity and healthcare costs. Given these advantages, ACTH-O warrants consideration for broader clinical adoption.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmeasured Health Disparities: Hidden Confounders in Survival Outcomes.","authors":"Yining Zhang, Mingtao Yu","doi":"10.1016/j.clbc.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.013","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologically Informed Decision-Making for PMRT in pT3N0M0 Luminal Breast Cancers (Protocol MF22-02): International Multicenter Real-World Data.","authors":"Atilla Soran, Melis Bahadir Gultekin, Bhanu Prasad Venkatesulu, Parul Nafees Barry, Caleb King, Rohit Bhargava, Hasan Karanlik, Ferah Yildiz, Aykut Soyder, Berk Goktepe, Kazim Senol, Caglar Guzel, Ebru Sen, Levent Yeniay, Ahmet Dag, Didem Can Trabulus, Alper Coskun, Hagigat Veliyeva, Zafer Utkan, Berkay Demirors, Efe Sezgin, John Austin Vargo","doi":"10.1016/j.clbc.2025.04.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.012","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines do not list definitive recommendations for postmastectomy radiation therapy (PMRT) in patients with luminal pT3N0M0 breast cancer (BC). Increased data suggests de-escalation of radiation therapy (RT) in genomically defined biologically favorable luminal BCs. The goal of this study is to determine whether PMRT can be safely omitted for this specific subgroup of patients.</p><p><strong>Methods and materials: </strong>Two hundred and 2 women from 16 centers with pT3N0M0 hormone receptor (HR) positive, HER2 negative BC who underwent mastectomy were retrospectively analyzed. No patients received neoadjuvant chemotherapy. Three patients were excluded because of positive surgical margins. Patients were divided into 2 groups: PMRT (n = 130) and no PMRT (n = 69). Groups were compared in terms of overall survival (OS), loco-regional recurrence (LRR) rate, and distant metastases (DM) in light of the Magee Equations Score (MS), menopausal status/age, axillary surgery, pathology, lymphovascular invasion (LVI), adjuvant chemotherapy, and adjuvant endocrine therapy.</p><p><strong>Results: </strong>The majority of the patients had invasive ductal carcinoma (49%, n = 98). There was no significant difference regarding tumor size, axillary surgery, and adjuvant endocrine therapy between the 2 groups (P = .82, P = .28, P = .12, respectively). LVI was 19% (n = 39), and it was greater in the PMRT group (25% vs. 10%; P = .01). Patients in the PMRT group received more chemotherapy (66% vs. 30%; P < .001), had more grade 3 tumors (28% vs. 9%, P = .005), and were more premenopausal (49% vs. 22%; P = .0001). At a median follow-up of 51.3 months for the no PMRT group and 65.9 months for the PMRT group (P = .041), 9% (n = 6) of patients from the no PMRT group and 2% (n = 3) from the PMRT group developed LRR (P = .047). There was no difference in local recurrence (1% in no PMRT group vs. 2% in PMRT group; P = .7) and distant recurrence (7% in no PMRT group vs. 3% in PMRT group; P = .16) in patients who received PMRT and no PMRT. Further comparison of the LRR in the no PMRT and PMRT groups in patients with an MS < 18 did not show a significant difference (3% vs. 4%; P = .64). However, among patients with an MS ≥ 18, no PMRT group had a higher LRR rate compared to the PMRT group (11% vs. 2%; P = .01). In patients with an MS ≥ 18, the administration of PMRT correlates with statistically significantly better LRR-free survival (HR 0.19; 95% CI 0.05-0.79; P = .02).</p><p><strong>Conclusions: </strong>Our findings imply that when considering PMRT for patients with pT3N0M0, HR-positive, and HER2-negative BC, clinicians can benefit from a combination of pathological risk factors and recurrence prediction models. Patients with MS < 18 experience a comparable rate of recurrence irrespective of PMRT, while those with MS ≥ 18 have higher rates of LRR and thus should not omit PMRT.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations in the Meta-Analysis of Breast-Conserving Therapy for Multifocal Disease.","authors":"Muharrem Oner, Kefah Mokbel","doi":"10.1016/j.clbc.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.010","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}